Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | APAF1 | O14727 | 1/20 | 0.70 |
| ▸ | RECQL | P46063 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | MPO | P05164 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30912052 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL1362995 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL29361050 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL29556806 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL891879 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL30833074 | 0.89 | SMN1; SMN2 (0.81) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| Cystine SCHEMBL30036693 | 0.87 | SMN1; SMN2 (0.76) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL4987528 | 0.87 | SMN1; SMN2 (0.76) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL9449541 | 0.87 | SMN1; SMN2 (0.77) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL29388323 | 0.86 | SMN1; SMN2 (0.74) | SMN1; SMN2KDM4EMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636325-B2 | Probiotic compositions for treating and preventing colorectal cancer | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2026-05-26 | — | — | US | claimed |
| CN-122074042-A | Histamine H1 receptor antagonistic composition | 株式会社明治 | 2026-05-22 | — | — | CN | claimed |
| CN-122038195-A | Lai Xingba Herbacea strain Reichenbachiella sp.H2 and application thereof | 广西大学 | 2026-05-15 | — | — | CN | claimed |
| EP-4739326-A2 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR Biome ApS (DK) | 2026-05-13 | — | — | EP | claimed |
| CN-122012352-A | Lactobacillus gasseri for efficiently utilizing tryptophan to produce indole-3-lactic acid and application thereof | 乾生(宁波)科技有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122017247-A | Plasma metabolism marker for distinguishing benign thyroid diseases from early thyroid cancers and application of plasma metabolism marker | 哈尔滨脉图精准技术有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-121610414-B | Saliva combined lactobacillus and application thereof in preparation of medicines for relieving parkinsonism | 南昌大学 | 2026-05-12 | — | — | CN | claimed |
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MARVELBIOME INC (US) | 2026-04-02 | — | — | US | claimed |
| EP-4701443-A1 | NUTRITIONAL COMPOSITION | Société des Produits Nestlé S.A. (CH) | 2026-03-04 | — | — | EP | claimed |
| US-20260027161-A1 | BACTERIAL STRAINS FOR TREATING DISEASE | MICROBA IP PTY LTD (AU) | 2026-01-29 | — | — | US | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0673782-B1 | Recording sheets containing pyrrole, pyrrolidine, pyridine, piperidine, homopiperidine, quinoline, isoquinoline, quinuclidine, indole, and indazole compounds | XEROX CORP (US) | 2000-06-14 | — | — | EP | claimed |
| US-5657064-A | Recording sheets containing pyrrole, pyrrolidine, pyridine, piperidine, homopiperidine, quinoline, isoquinoline, quinuclidine, indole, and indazole compounds | XEROX CORPORATION (US) | 1997-08-12 | — | — | US | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0673782-A2 | Recording sheets containing pyrrole, pyrrolidine, pyridine, piperidine, homopiperidine, quinoline, isoquinoline, quinuclidine, indole, and indazole compounds | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | claimed |
| US-4363815-A | Alpha hydroxyacids, alpha ketoacids and their use in treating skin conditions | YU RUEY J | 1982-12-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | IAPP, GPR119, FAHD1 | SMN1; SMN2 322/4885KDM4E 4749/4885MAPT 132/4885 |
| US-12636325-B2 | Probiotic compositions for treating and preventing colorectal cancer | LCT, SI, LDHA | SMN1; SMN2 3817/4885KDM4E 3413/4885MAPT 935/4885 |
| US-20260027161-A1 | BACTERIAL STRAINS FOR TREATING DISEASE | VIP, SI, ALPI | SMN1; SMN2 2370/4885KDM4E 4679/4885MAPT 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.